The competition between two types of JAK inhibitors in the field of juvenile atopic dermatitis has begun in earnest. Following AbbVie Korea's Rinvoq last April, Pfizer Korea's Cibinqo was covered by insurance for the indication of atopic dermatitis in children and adolescents from this month (July).

Cibinqo stopped the reimbursement process after passing the Pharmaceutical Reimbursement Criteria Subcommittee of the Health Insurance Review and Assessment Service in August last year, and at the beginning of this year, it expanded the scope from adults to teenagers over 12 years of age and resubmitted the application for reimbursement. After passing the Pharmaceutical Reimbursement Evaluation Committee in